๐ญ๐ฐSCMP TechnologyโขStalecollected in 12m
Akeso's ivonescimab shows strong results in lung cancer trials
๐กSee how AI-driven biotech 'DeepSeek moments' are disrupting the $20B lung cancer drug market.
โก 30-Second TL;DR
What Changed
Ivonescimab phase three trial successfully reduced the risk of death in lung cancer patients.
Why It Matters
The success of ivonescimab validates the application of advanced computational biology and AI-driven drug discovery pipelines. It signals a shift in how biotech firms leverage data-heavy models to accelerate clinical breakthroughs.
What To Do Next
Monitor Akeso's clinical data disclosure patterns to understand how they integrate AI-driven predictive modeling into their drug development lifecycle.
Who should care:Researchers & Academics
Key Points
- โขIvonescimab phase three trial successfully reduced the risk of death in lung cancer patients.
- โขThe drug is positioned to become a backbone therapy for non-small cell lung cancer.
- โขAnalysts have revised target prices upward following the positive clinical data.
- โขThe drug is expanding its potential approved uses in the US$20 billion global market.
๐ง Deep Insight
Web-grounded analysis with 20 cited sources.
๐ Enhanced Key Takeaways
- โขThe HARMONi-6 trial demonstrated a statistically significant 34% reduction in the risk of death for patients treated with ivonescimab plus chemotherapy, compared to tislelizumab plus chemotherapy, in first-line advanced squamous non-small cell lung cancer (NSCLC).
- โขThis marks a historic achievement for China's biotech industry, as ivonescimab is the first China-originated investigational oncology drug to be selected for presentation in a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
- โขIvonescimab has previously shown superior progression-free survival (PFS) compared to pembrolizumab monotherapy in first-line PD-L1-positive NSCLC (HARMONi-2 trial) and has demonstrated dual overall survival (OS) and PFS benefits in EGFR-mutant non-squamous NSCLC after TKI failure.
- โขThe survival benefit observed in the HARMONi-6 trial was consistent across various patient subgroups, including those with PD-L1-negative and PD-L1-positive tumors, notably showing a 36% reduction in death risk for patients with very low PD-L1 expression (<1%).
- โขAkeso has partnered with Summit Therapeutics for the development and commercialization of ivonescimab in key global markets including the United States, Canada, Europe, and Japan, indicating a significant international collaboration.
๐ Competitor Analysisโธ Show
| Feature/Drug | Ivonescimab (Akeso/Summit Therapeutics) | Tislelizumab (BeOne Medicines/BeiGene) | Pembrolizumab (Merck's Keytruda) |
|---|---|---|---|
| Drug Class | First-in-class PD-1/VEGF bispecific antibody | PD-1 inhibitor | PD-1 inhibitor |
| Mechanism | Dual blockade of PD-1 and VEGF-A, with cooperative binding and tetravalent structure. | Blocks PD-1 to reactivate T-cells. | Blocks PD-1 to reactivate T-cells. |
| HARMONi-6 (sq-NSCLC) | Reduced risk of death by 34% vs. tislelizumab + chemo. Median OS: 27.9 months. | Control arm in HARMONi-6. Median OS: 23.7 months (with chemo). | Not directly compared in HARMONi-6. |
| HARMONi-2 (PD-L1+ NSCLC) | Median PFS: 11.1 months (monotherapy). | Not directly compared in HARMONi-2. | Median PFS: 5.8 months (monotherapy). |
| Safety Profile | Favorable, comparable to tislelizumab + chemo in HARMONi-6, though higher rates of hemorrhage (24.8% vs 12.1% any grade) and blood clots (9 vs 4) were noted. | Favorable safety profile in HARMONi-6 control arm. | Acceptable, with grade โฅ3 TRAEs of 16% in HARMONi-2. |
| Approval Status | Approved in China (May 2024). Investigational in US, EU, Japan. | Approved in China for first-line squamous NSCLC. Approved in EU for various indications. | Widely approved globally for various cancer types, including NSCLC. |
| Global Market | Positioned as potential backbone therapy in US$20 billion global market. | Generated US$737 million in global sales in 2025. | Leading immunotherapy with significant market share. |
๐ ๏ธ Technical Deep Dive
- Ivonescimab is a novel, first-in-class, IgG1-scFv humanized, tetravalent bispecific monoclonal antibody.
- It is engineered to simultaneously target two critical pathways: Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor A (VEGF-A).
- A key technical feature is its unique cooperative binding mechanism, where the presence of one target (e.g., VEGF) reciprocally augments its binding affinity for the other target (PD-1), leading to over 18-fold increased binding affinity to PD-1 in the presence of VEGF in vitro.
- This tetravalent structure and cooperative binding are designed to enhance its preferential accumulation and activity within the tumor microenvironment, where both PD-1 and VEGF are often highly expressed, potentially improving efficacy and reducing systemic side effects.
- By blocking PD-1, ivonescimab reactivates cytotoxic T-cells to mount an anti-tumor response, while its inhibition of VEGF-A suppresses tumor angiogenesis, normalizes tumor vasculature, and enhances immune cell infiltration into the tumor.
- The antibody features an Fc-silent IgG1 design, which results in reduced FcฮณR interactions and minimal Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP) activities, contributing to its observed safety profile.
๐ฎ Future ImplicationsAI analysis grounded in cited sources
Ivonescimab is poised to become a new standard of care for advanced squamous non-small cell lung cancer.
Its statistically significant and clinically meaningful improvement in overall survival in a head-to-head Phase III trial against an established PD-1 inhibitor plus chemotherapy sets a new benchmark for treatment efficacy.
The success of ivonescimab will significantly elevate the global standing and adoption of innovative oncology drugs originating from China.
Being the first China-originated investigational oncology drug to be featured in an ASCO Plenary Session underscores a pivotal shift in global biotech innovation and recognition, often referred to as China's 'DeepSeek moment' in biotech.
The bispecific antibody class targeting both PD-1 and VEGF will see accelerated development and investment.
Ivonescimab's strong clinical results validate the therapeutic potential of this dual-target approach, likely encouraging further research and development in similar bispecific molecules for various cancer types.
โณ Timeline
2022-12
Summit Therapeutics licenses ivonescimab rights for major global markets from Akeso.
2023-08
New Drug Application (NDA) for ivonescimab accepted by China's NMPA CDE.
2023-10
Ivonescimab's novel cooperative binding and tetravalent structure mechanism presented at SITC 2023.
2024-05
Ivonescimab receives approval in China from the National Medical Products Administration (NMPA).
2025-03
HARMONi-2 trial results published in The Lancet, showing ivonescimab's superior PFS vs. pembrolizumab in PD-L1+ NSCLC.
2026-02
Ivonescimab granted its fifth Breakthrough Therapy Designation by China's NMPA for advanced biliary tract cancer.
2026-05
HARMONi-6 trial results presented at ASCO Plenary Session, demonstrating significant overall survival benefit in squamous NSCLC.
๐ Sources (20)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
๐ฐ
Weekly AI Recap
Read this week's curated digest of top AI events โ
๐Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: SCMP Technology โ